[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335592-105":59,"doc-detail-335592-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","identication-of-her2-positive-breast-cancer-molecular-subtypes-with-potential-clinical-implications-in-the-altto-clinical-trial","Identiﬁcation of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial","","HER2-positive breast cancer outcomes and sensitivity to HER2-targeted therapy are shaped by tumor and microenvironment features, yet molecular heterogeneity has lacked sufficient resolution. Using gene expression profiling of HER2-positive patients treated with adjuvant trastuzumab in the ALTTO trial, five distant-recurrence-associated subtypes were identified and biologically validated, including immune-enriched, proliferative/metabolic-enriched, mesenchymal/stroma-enriched, luminal, and ERBB2-dependent. Prognostic and predictive relevance was assessed in external cohorts, revealing distinct survival and pathological complete response patterns that support biology-driven treatment strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/identication-of-her2-positive-breast-cancer-molecular-subtypes-with-potential-clinical-implications-in-the-altto-clinical-trial/335592/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/identication-of-her2-positive-breast-cancer-molecular-subtypes-with-potential-clinical-implications-in-the-altto-clinical-trial/335592.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical trial data were used to identify the HER2-positive molecular subtypes?","Question",{"text":112,"@type":113},"Gene expression profiling was performed on HER2-positive breast cancers from patients receiving adjuvant trastuzumab in the ALTTO clinical trial (NCT00490139).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many molecular subtypes were identified, and what are they?",{"text":117,"@type":113},"Five subtypes were identified: immune-enriched, proliferative/metabolic-enriched, mesenchymal/stroma-enriched, luminal, and ERBB2-dependent.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study show about survival and pathological complete response across subtypes?",{"text":121,"@type":113},"Immune-enriched tumors showed better survival, while mesenchymal/stroma-enriched and proliferative/metabolic-enriched tumors contrasted with that outcome. Luminal and ERBB2-dependent tumors were associated with low and high rates of pathological complete response, respectively.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335592,1790171340,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","Article [https://doi.org/10.1038/s41467-024-54621-3](https://doi.org/10.1038/s41467-024-54621-3)  \nIdentiﬁcation of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial  \nReceived: 26 March 2024  \n\n| Accepted: 13 November 2024 |\n| --- |\n| |\n| Check for updates |\n\nMattia Rediti 1,2, David Venet1, Andrea Joaquin Garcia1, Marion Maetens3, Delphine Vincent1, Samira Majjaj1, Sarra El-Abed4, Serena Di Cosimo 5, Takayuki Ueno 6, Miguel Izquierdo7, Martine Piccart8, Lajos Pusztai 9, Sherene Loi 10,11, Roberto Salgado 10,12, Giuseppe Viale13, Françoise Rothé1 & Christos Sotiriou 1   \nIn HER2-positive breast cancer, clinical outcome and sensitivity to HER2-targeted therapies are inﬂuenced by both tumor and microenvironment features. However, we are currently unable to depict the molecular heterogeneity of this disease with sufﬁcient granularity. Here, by performing gene expression proﬁling in HER2-positive breast cancers from patients receiving adjuvant trastuzumab in the ALTTO clinical trial (NCT00490139), we identify and characterize ﬁve molecular subtypes associated with the risk of distant recurrence: immune-enriched, proliferative/metabolic-enriched, mesenchymal/stroma-enriched, luminal, and ERBB2-dependent. Additionally, we validate the biological proﬁles of the subtypes and explore their prognostic/ predictive value in external cohorts, namely the NeoALTTO trial (NCT00553358), SCAN-B (NCT02306096), I-SPY2 (NCT01042379), METABRICand TCGA. Immune-enriched tumors present better survival outcomes, in contrast to mesenchymal/stroma-enriched and proliferative/metabolic-enriched tumors, while luminalandERBB2-dependent tumors are characterized by low and high rates of pathological complete response, respectively. Of note, these molecular subtypes provide the rationale for treatment approaches leveraging the heterogeneous biology of HER2-positive breast cancer.  \nSince the demonstration of the prognostic and predictive role of HER2 ampliﬁcation in breast cancer1, the clinical outcome of early-stage HER2-positive breast cancer has been profoundly reshaped. Indeed, the introduction of the monoclonal anti-HER2 antibody trastuzumab  \ninthe adjuvant setting2 paved the way for a revolution in the treatment landscape of HER2-positive breast cancer, and was followed by the development of effective treatment strategies in both the adjuvant3–8 and neoadjuvant/post-operative setting9–14.  \n1Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H. U. B), Université Libre de Bruxelles (ULB), Brussels, Belgium. 2IFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy. 3Laboratory for Translational Breast Cancer Research, KU Leuven, Leuven, Belgium. 4Breast International Group, Brussels, Belgium. 5Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 6Breast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. 7Novartis Pharma AG, Basel, Switzerland. 8Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U. B), Université Libre de Bruxelles (ULB), Brussels, Belgium. 9Yale School of Medicine, Yale Cancer Center, New Haven, CT, USA. 10Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 11The Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, VIC, Australia. 12Department of Pathology, ZAS Hospitals, Antwerp, Belgium. 13Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy. e-mail: [christos.sotiriou@hubruxelles.be](christos.sotiriou@hubruxelles.be)  \nWhile the mainstay of HER2-positive breast cancer treatment is represented by targeting the HER2 tyrosine kinase, the presence of higher levels of the HER2 protein alone is not sufﬁcient to guarantee durable responses. Several resistance mechanisms may occur, and the pre","cbCailBGtfpWbDda","https://ap.wps.com/l/cbCailBGtfpWbDda","pdf",2089894,17,"English","# Introduction\n# Rationale and clinical background\n# Molecular profiling approach in ALTTO\n# Subtype characterization and validation\n# Prognostic and predictive value in external cohorts\n# Clinical implications for HER2-positive treatment","[{\"question\":\"What clinical trial data were used to identify the HER2-positive molecular subtypes?\",\"answer\":\"Gene expression profiling was performed on HER2-positive breast cancers from patients receiving adjuvant trastuzumab in the ALTTO clinical trial (NCT00490139).\"},{\"question\":\"How many molecular subtypes were identified, and what are they?\",\"answer\":\"Five subtypes were identified: immune-enriched, proliferative/metabolic-enriched, mesenchymal/stroma-enriched, luminal, and ERBB2-dependent.\"},{\"question\":\"What did the study show about survival and pathological complete response across subtypes?\",\"answer\":\"Immune-enriched tumors showed better survival, while mesenchymal/stroma-enriched and proliferative/metabolic-enriched tumors contrasted with that outcome. Luminal and ERBB2-dependent tumors were associated with low and high rates of pathological complete response, respectively.\"}]","Identiﬁcation of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial | PDF",1790011546,43]